stockrowDenali Therapeutics Inc.
DNLI Healthcare Biotechnology
Denali Therapeutics Inc.’s revenue for fiscal 2023 (year ended December 2023) was $330.5 million, up 204.7% from fiscal 2022.
- Revenue
- −94.0%
- EPS
- +150.3%
- Free cash flow
- −11.8%
- Total debt
- −1.89%
Quarter to September 2026, against a year earlier
Follow DNLI
Alert me
Denali Therapeutics Inc. (DNLI) Shares outstanding
Denali Therapeutics Inc.'s shares outstanding at the end of fiscal 2025 was $172.6M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $192.1M. Over the past ten years it has ranged from $3.0M (fiscal 2015) to $172.6M (fiscal 2025) — the current reading is the highest in ten years. Denali Therapeutics Inc. ranks 53rd of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $172.6M | 4.97% |
| FY2024 | $164.5M | 19.73% |
| FY2023 | $137.4M | 9.43% |
| FY2022 | $125.5M | 3.30% |
| FY2021 | $121.5M | 7.83% |
| FY2020 | $112.7M | 17.88% |
| FY2019 | $95.6M | 3.22% |
| FY2018 | $92.6M | 518.97% |
| FY2017 | $15.0M | 132.90% |
| FY2016 | $6.4M | 113.74% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $192.1M | 2.54% |
| Jun 2026 | $187.3M | 0.36% |
| Mar 2026 | $186.6M | 8.10% |
| Dec 2025 | $172.6M | 0.13% |
| 35 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| DNLI Denali Therapeutics Inc. | $192.1M |
| DYN Dyne Therapeutics, Inc. compare | $165.5M |
| VKTX Viking Therapeutics, Inc. compare | $118.1M |
| VRDN Viridian Therapeutics, Inc. compare | $107.9M |
| IDYA IDEAYA Biosciences, Inc. compare | $102.9M |
| ELVN Enliven Therapeutics, Inc. compare | $66.2M |
| CELC Celcuity, Inc. compare | $54.8M |
| TARS Tarsus Pharmaceuticals, Inc. compare | $46.4M |
| TLX Telix Pharmaceuticals Limited compare | — |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on DNLI
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement